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The Leishmania donovani nucleoside hydrolase (NH36) and NH A34480 of Leishmania 
amazonensis share 93% of sequence identity. In mice, the NH36 induced protection 
against visceral leishmaniasis is mediated by a CD4+ T cell response against its 
C-terminal domain (F3). Besides this CD4+ Th1 response, prevention and cure of L. 
amazonensis infection require also additional CD8+ and regulatory T-cell responses 
to the NH36 N-terminal (F1 domain). We investigated if mice vaccination with F1 and 
F3 domains cloned in tandem, in a recombinant chimera, with saponin, optimizes the 
vaccine efficacy against L. amazonensis infection above the levels promoted by the two 
admixed domains or by each domain independently. The chimera induced the highest 
IgA, IgG, and IgG2a anti-NH36 antibody, IDR, IFN-γ, and IL-10 responses, while TNF-α 
was more secreted by mice vaccinated with F3 or all F3-contaning vaccines. Additionally, 
the chimera and the F1 vaccine also induced the highest proportions of CD4+ and CD8+ 
T cells secreting IL-2, TNF-α, or IFN-γ alone, TNF-α in combination with IL-2 or IFN-γ, 
and of CD4+ multifunctional cells secreting IL-2, TNF-α, and IFN-γ. Correlating with the 
immunological results, the strongest reductions of skin lesions sizes were determined by 
the admixed domains (80%) and by the chimera (84%), which also promoted the most 
pronounced and significant reduction of the parasite load (99.8%). Thus, the epitope 
presentation in a recombinant chimera optimizes immunogenicity and efficacy above the 
levels induced by the independent or admixed F1 and F3 domains. The multiparameter 
analysis disclosed that the Th1-CD4+ T helper response induced by the chimera is mainly 
directed against its FRYPRPKHCHTQVA epitope. Additionally, the YPPEFKTKL epitope 
of F1 induced the second most important CD4+ T cell response, and, followed by the 
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inTrODUcTiOn
Leishmaniasis is a complex of protozoan vector-borne diseases 
of recent increased worldwide incidence (1). Clinical manifes-
tations of the disease range from visceral leishmaniasis (VL), 
the most severe and fatal syndrome with 400,000 new cases/
year, characterized by a strong suppression of the CD4+ T-cell 
response, to tegumentary leishmaniasis, with 7 to 1.2 million 
new annual cases and variable degrees of T-cell immunity (2). 
Clinical cases of cutaneous leishmaniasis (CL), the most benign 
form of tegumentary leishmaniasis, show skin ulcers and a T 
cell-mediated active immune response, which is often responsible 
of self-healing or worsening of the disease (2). Mucocutaneous 
leishmaniasis (MCL), on the other hand, involves an exacerbated 
immune inflammatory response and lesions of cutaneous and 
mucosal tissues, while diffuse cutaneous leishmaniasis (DCL), the 
anergic form of disease, is associated to high Leishmania-specific 
inhibition of the T-cell responses (3). A few patients also develop 
the borderline disseminated leishmaniasis (4).
Afghanistan, Algeria, Colombia, Brazil, Iran, Syria, Ethiopia, 
North Sudan, Costa Rica, and Peru are the 10 countries with 
higher incidence of CL, and together they account for 70–75% of 
the estimated global occurrence (2). Regarding the ethyological 
agents of tegumentary leishmaniasis, Leishmania amazonensis 
is a causative agent of CL, MCL, and DCL in Northern, South 
America, and Brazil (3–7).
Chemotherapy of leishmaniasis is highly toxic, and many 
cases of resistance or recurrent disease were reported (8–10). 
Alternatively, vaccine-mediated prevention or cure of CL was 
assayed with first generation formulations since the 80s, achiev-
ing, however, no more than 50% efficacy (8, 11). Only one vaccine 
based on L. amazonensis lysate is licensed at present for immuno-
chemotherapy in Brazil (8).
Since three licensed vaccines against canine VL are available at 
present (12–14), one feasible approach to induce cross-protection 
against CL would be to use the vaccine antigens that are conserved 
in the Leishmania genus (15, 16) and already demonstrated to 
confer protection against VL (12, 17–19), the most immunosup-
pressive and severe form of the disease.
The Leishmania donovani nucleoside hydrolase (NH36) (17) 
is the main antigen of the Leishmune® vaccine, the first licensed 
veterinary vaccine against canine VL (12, 18). Leishmune® shows 
76–80% vaccine efficacy (18, 19), and its use in endemic areas 
already promoted the decrease of the canine and the human 
incidence of VL (12).
Nucleoside hydrolases are enzymes of the DNA metabolism 
of bacteria, fungi, and protozoa which release exogenous purines 
or pyrimidines from nucleosides, in microorganisms that are not 
able to synthetize them, enabling in this way an efficient pathogen 
replication. They are absent in mammals (20, 21).
Vaccination with the NH of L. donovani, NH36, in its native 
form, protected mice against L. donovani infection (22), and in 
its DNA or recombinant protein forms induced efficacy against 
mice (17, 23, 24) and dog infections by Leishmania chagasi (25), 
and against mice challenged with Leishmania mexicana (23), 
Leishmania major (26), and L. amazonensis (27–29), the respec-
tive agents of cutaneous and diffuse leishmaniasis. NHs are 
considered strong phylogenetic markers of the genus Leishmania 
(15, 16), and their amino acid sequences are strongly conserved 
(29, 30). In fact, the sequence of L. donovani NH36 is homologous 
to the NH sequences of all the studied species of Leishmania: L. 
major (95%) (31), L. chagasi (99%), Leishmania infantum (99%), 
L. amazonensis (93%) (28), L. mexicana (93%), Leishmania bra-
ziliensis (84%), and Leishmania tropica (97%) (32).
Therefore, NH36 becomes a good candidate for the devel-
opment of a cross-protective and universal vaccine against 
leishmaniasis. Using recombinant generated proteins covering 
the whole sequence of NH36, and saponin, in previous work, we 
demonstrated that protection against mice VL is mediated by a 
CD4+ T cell response against epitopes of the NH36 C-terminal 
domain (F3) (17). On the other hand, prevention (28) and cure 
of mice CL (29) caused by L. amazonensis are determined by a 
CD4+-Th1 cell-mediated response toward the F3 protein and a 
CD8+ and regulatory T-cell responses directed to the N-terminal 
(F1) domain of NH36, which promoted simultaneous increased 
secretions of IFN-γ, TNF-α, and IL-10 (29).
Additionally, the F3 vaccine promoted in mice a 36 and 40% 
respective higher average protection than those generated by the 
NH36-vaccine against VL, induced by L. chagasi (17), and CL, 
caused by L. amazonensis (28). These results confirmed that the 
use of the domain containing the relevant epitopes enhances the 
efficacy over that induced by the cognate whole protein (33).
Multisubunit vaccines against leishmanial infection have been 
shown to be more promising (34). Additionally, the most efficient 
protection is considered to be determined by diverse T cells that 
respond to a group of the pathogen-derived epitopes (35). Recent 
research in immunity to leishmaniasis disclosed the importance 
of multifunctional CD4+ and CD8+ T cells in the generation of a 
Th1 response to control infection (34, 36, 37). According to that, 
it has been suggested that the in  silico tools should be used to 
DVAGIVGVPVAAGCT, FMLQILDFYTKVYE, and ELLAITTVVGNQ sequences, also the 
most potent CD8+ T cell responses and IL-10 secretion. Remarkably, the YPPEFKTKL 
epitope shows high amino acid identity with a multipotent PADRE sequence and stim-
ulates simultaneously the CD4+, CD8+ T cell, and a probable T regulatory response. 
With this approach, we advanced in the design of a NH36 polytope vaccine capable of 
inducing cross-protection to cutaneous leishmaniasis.
Keywords: nucleoside hydrolases, T-cell epitope vaccines, visceral and cutaneous leishmaniasis, Leishmania 
amazonensis, PaDre epitopes
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search in the Leishmania genome for potential candidates with 
both CD4+ and CD8+ T cell-stimulating competences. Epitope 
mapping could then be used to design a polyepitope vaccine 
that could carry conserved epitopes, which bind to many HLA 
or MHC allotypes, or which are present in many species of a 
Leishmania genus (34).
Although the whole NH36 protein would be easier to work 
with, it would be also much less potent. In fact, according to the 
philosophy of the development of T-epitope vaccines, the whole 
cognate protein is less potent than the domains that contain the 
important epitopes. The domains are also more immunogenic 
than the isolated epitopes. Our aim, in this investigation, was to 
increase potency and optimize the vaccine. In agreement to that, 
we were able to show that a combination of these domains in a 
chimera even enhances the protective efficacy demonstrated for 
each domain independently. Our results support that the use of 
the domain containing the relevant epitopes enhances the vaccine 
efficacy over that induced by the cognate whole protein (33).
In fact, we evaluated if the administration of F1 and F3 domains 
of NH36 expressed in tandem, as a recombinant chimera, opti-
mizes the immunogenicity and vaccine efficacy against mice 
infection by L. amazonensis, above the levels promoted by the two 
admixed domains and by each protein administered alone. We 
additionally identified the most important epitopes of F1 and F3 
responsible for the generation of the cellular immune response. 
In this investigation, we aimed to progress in the development 
of a universal NH36 T-cell epitope vaccine capable of protecting 
against the infection by L. amazonensis.
MaTerials anD MeThODs
ethical statement
This study was carried out in accordance with the recommenda-
tions of National Institutes of Health, USA. The protocol was 
approved by the Comissão de Avaliação da Utilização de Animais 
em Pesquisa do Centro de Ciência da Saúde (CEUA), Universidad 
Federal do Rio de Janeiro (CONCEA, Brazil, 01200.001568/2013-
87, IMPPG-016).
recombinant antigens expression and 
Purification and epitopes
NH36 is composed of 314 amino acids (Genbank access number 
AY007193, SwissProt-UniProt access number Q8WQX2-LEIDO). 
The N-terminal (F1, amino acid sequences 1–103), the central 
(F2, amino acids 104–198), and the C-terminal (F3, amino acids 
199–314) domains were cloned in the pET28 plasmid system, 
between the restriction sites of NcoI and XhoI (17). Furthermore, 
the F1F3 recombinant chimera containing the sequence of the 
F1 followed by the F3 protein, cloned between the restriction 
sites of NcoI and XhoI was obtained with optimized codons in 
the PET28b expression vector by GenScript (NJ, USA). All the 
recombinant proteins used in this investigation were expressed 
with a six His-Tag at their C-terminals.
For protein expression, pET28bNH36, pET28bF1, pET28bF3, 
or pET28bF1F3-transformed E. coli BI21DE3 bacteria were 
amplified into 2  l of LB culture medium with kanamycin. 
Expression was induced with 1  mM IPTG (isopropyl-beta-
d-thiogalactopyranoside—Fermentas) for 4 h at 37°C, and cul-
tures were centrifuged. The pellets were sonicated and further 
centrifuged for 20 min under 14,000 rpm at 4°C. The recombi-
nant proteins were more concentrated in the pellets, which were 
purified by affinity column chromatography with Ni-NTA resin 
according to the manufacturer’s instructions (Qiagen). Briefly, 
each pellet was incubated with 10–15 ml urea buffer (8 M urea, 
1 M Na2HPO4, 1 M NaH2PO4, and 1 M Tris–HCl) pH 8.0, for 
2 h, on ice. Then, the suspension was homogenized by successive 
passages through 20 ml syringes with 1.2 mm ×  40 mm nee-
dles, until complete dissolution and centrifuged for 15 min at 
14,000 rpm at 4°C. The supernatants containing the solubilized 
proteins were loaded on the Ni-NTA column previously equili-
brated with urea buffer. Then, the column was washed with 5 
volumes of urea buffer, pH 8.0, for removal of non-specifically 
bound proteins and with additional 5 volumes of urea buffer, pH 
6.4–6.5, for removal of bacterial proteins containing His resi-
dues. The recombinant antigens were recovered in 10 volumes 
of urea buffer pH 4.5, dialyzed overnight against PBS at 4°C, 
and preserved with 1 mM PMSF and 5% glycerol at −80°C (17). 
The absence of LPS was confirmed using the LAL QCL-1000 
kit (Lonza).
Furthermore, CD4+ T cell epitopes predicted by the Protean 
Pad program based on the A. Sette algorithm for the H2d haplo-
type of Balb/c mice (IAd and IEd alleles) (17) and the CD8+ T cell 
epitopes (H2 Ld haplotype), identified by the HLA peptide motif 
search1 and the SYFPEITHI2 programs (17) were synthetized by 
GenScript (NJ, USA). A model of the structure of the NH36 mon-
omer and of the spatial distribution of the predicted epitopes in 
F1 and F3 is represented in Figure S1 in Supplementary Material.
Vaccine efficacy assay
Groups of BALB/c females (2-month old) were randomized by 
corporal weight and immunized with three subcutaneous doses 
of each respective vaccine: F1 (100 µg), F3 (100 µg), F1 (50 µg), 
and F3 (50 µg) administered as a simple mixture (F1 + F3), and 
F1F3 chimera (100 or 200  µg). All antigens were formulated 
with 100 µg of Riedel de Haen saponin (Sigma, St. Louis, MO, 
USA) in 0.2 ml of 0.9% NaCl saline solution and injected sub-
cutaneously in the back, at weekly intervals (17, 28, 29). Control 
animals received only saline. Mice were infected subcutaneously 
in the right hind footpads with 106 stationary phase infective 
promastigotes of L. amazonensis IFLA/BR/67/PH8, 10 days after 
the last vaccine dose. Briefly, infective parasites were obtained 
from hamsters footpads in 10% fetal calf serum, 50  U penicil-
lin, and 50 µg streptomycin/ml (Cultilab, Brazil) supplemented 
Schneider’s Drosophila medium (Sigma). Parasites where then 
cultured using a 1/5 serial dilution, in 24-well plates, at 26°C, 
during 3  days. On day 4, 400  µl of promastigote suspensions 
was amplified through three successive passages in Schneider’s 
supplemented medium and finally, the stationary-phase parasites 
1 http://bimas.dcrt.nih.gov/molbio/hla_bind/
2 http://www.syfpeithi.de/
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were centrifuged, washed twice, suspended in saline solution, 
counted in a hemocytometer, and used for infection.
The evolution of lesion sizes in footpads was monitored weekly, 
with a Mitutoyo® pachymeter. Measures of the infected footpads 
were subtracted from the contra-lateral controls injected only 
with saline.
At week 12, mice were euthanized with CO2 and their parasite 
load determined by a limiting dilution assay. Briefly, the infected 
paws were removed under aseptic conditions and washed with 
Schneider’s medium. Fragments of bones, nails, and skin were 
chirurgically removed. The remaining tissue was chopped into 
small pieces and suspended into 1 ml supplemented Schneider’s 
medium. A 1/5 serial dilution of this suspension was obtained 
in a 24-well plate that was further incubated at 26°C for 4 days, 
with daily observation in an inverted microscope. The number of 
promastigotes present at the last well containing visible parasites 
was quantified in a hemocytometer.
The anti-NH36 antibody response was assessed in sera, 
and the intradermal response to leishmanial antigen, and 
the secretion and intracellular expression of cytokines by 
antigen-stimulated CD4 and CD8 lymphocytes were studied 
1  week after complete vaccination and on week 12 after 
infection.
antibody assay in sera
Anti-NH36 antibodies were assayed in the sera of mice, using a 
standard ELISA assay. Plates were treated with 2 µg NH36 per well 
in carbonate–bicarbonate buffer pH 9.6, washed with 0.018  M 
PBS, pH 7.2, 1% non-fat milk, and 0.05% Tween-20 buffer (PBS*), 
and further incubated with diluted sera samples in PBS* for 1 h 
at 37°C. Then, plates were washed and treated with peroxidase-
conjugated goat anti-mouse-IgA, IgM, IgG1, or IgG2a antibodies 
(1:4,000) (Southern Biotechnology Associates, Birmingham, 
AL, USA) or with protein-A-peroxidase (Kirkegaard & Perry 
Laboratories, Gaithersburg, MD, USA, EEUU) at 1:1,000 dilution 
in PBS*. Reaction was developed with ortho-phenylenediamine 
buffer (Sigma), interrupted with 1 N sulfuric acid, and monitored 
at 492  nm. Results were expressed as the mean of absorbance 
values of 1/100 diluted sera of each animal, in triplicates, in 
double-blind tests.
intradermal skin Test (iDr)
Mice were injected in their right front footpad with 0.1  ml 
0.9% NaCl saline solution containing the lysate of 107 freeze-
thawed stationary-phase L. amazonensis infective promastigotes 
obtained as described in Section “Vaccine Efficacy Assay.” The 
footpad swallow was monitored with a Mitutoyo apparatus, both 
before and at 0, 24, and 48 h after lysate injection. Each measure 
was subtracted from the values of the left front footpads injected 
with only saline (28).
secreted cytokines assay
Spleens were excised, and single-cell suspensions were pre-
pared in 1 ml RPMI medium (Sigma, Co) supplemented with 
10% fetal calf serum (Nutricell, Campinas, São Paulo, Brazil), 
1% l-glutamine, and 5  mM 2-β-mercaptoethanol. Then, cells 
were counted in a hemocytometer, distributed into a 96-well 
plate (106/well), and incubated with 5  µg/well NH36, or with 
no addition, for 72 h in vitro, at 37°C with 5% of CO2. Culture 
supernatants were collected and assayed for IFN-γ, TNF-α, 
and IL-10 using the OptEIA mouse ELISA Set II kits (Becton 
and Dickinson, BD-Biosciences, USA) according to the 
manufacturer’s instructions. The sensitivity of the assay was 
established with a range of 0–1,000 pg/ml for TNF-α and IL-10 
and of 0–200 pg/ml for IFN-γ. Reactions were developed using 
biotinylated anti-cytokine antibodies, streptavidin (SAv-HRP) 
enzymatic reagent, and TMB (Zymed, USA). Absorbances were 
monitored at 655 nm.
intracellular cytokine staining (ics) and 
Flow cytometry
Splenocytes suspended in RPMI medium were distributed into 
96-well Costar plates (106/well) and stimulated with 25  µg/ml 
recombinant NH36 or with no addition, for 24 h at 37°C with 
5% CO2 according to the results of previous experiments. The 
intracellular expression of IL-2, TNF-α, and IFN-γ by CD4+ and 
CD8+ T cells was determined by multiparameter analysis (36, 37) 
after incubation with 10 µg/ml brefeldin (Sigma) for 4 h at 37°C, 
5% CO2. After washing with FACS buffer (PBS containing 2% 
bovine fetal calf, 0.1% sodium azide), splenocytes were labeled 
for 20  min at 4°C, in the dark with rat anti-mouse-CD4FITC 
(clone GK1.5) and -CD8FITC (clone 53-6.7) monoclonal 
antibodies (R&D systems, Inc.). Cells were then fixed with 4% 
para-formaldehyde, washed and treated with FACS buffer 
containing 0.5% saponin (Sigma), and further stained with IFN-
γAPC, IL-2-PerCP-Cy5.5, and TNF-αPE monoclonal antibodies 
(BD-Pharmingen). For ICS, gating for CD4+ ad CD8+ T cells 
was performed, and 100,000 events were acquired in a Becton 
Dickinson FACScalibur. Data were analyzed using the FlowJo 
program (Tree Star, USA).
epitope assays
Splenocytes of mice vaccinated with the chimera (100 μg/dose) 
or saline solution and further challenged with 106 promastigotes 
of L. amazonensis were incubated in  vitro with 25  µg/ml of 
NH36, F1F3 chimera, each one of the CD4 predicted epitopes 
of F1 (ELLAITTVVGNQ and DVAGIVGVPVAAGCT) and F3 
domains (FMLQILDFYTKVYE, FRYPRPKHCCHTQVA, and 
KFWCLVIDALKRIG), with the highest scored CD8 predicted 
epitope of the F1 protein (YPPEKTKL), or with the mixture of 
all the epitopes, at week 11 after infection. The epitope-specific 
cellular immune response was studied through the analysis of 
the cytokine secretion to supernatants and by multiparameter 
cytometry, as described above.
statistical Methods
Means were compared by the Kruskal–Wallis and Mann–
Whitney methods. Spearman’s two-tailed correlation test was 
used for correlation analysis. Furthermore, the slope of the 
curves of variation of lesion sizes along the time was calculated as 
the best-fit values (GraphPad Prism6 software). All experiments 
were performed at least twice, and the indicated error bars are 
based on the SE.
FigUre 1 | chimera enhances the iga and, together with F3, the igM anti-nh36 antibody response. BALB/c mice were immunized with three 
subcutaneous doses of each respective vaccine: F1 (100 µg), F3 (100 µg), F1 (50 µg), and F3 (50 µg) administered as a simple mixture (F1 + F3), and F1F3 chimera 
(100 or 200 µg), all formulated in 100 µg of saponin. Anti-NH36 antibodies were measured by an ELISA assay in the sera of mice after vaccination (a,c) and on 
week 12 after infection with Leishmania amazonensis (B,D). Data are means and individual results of two independent experiments, each one with 8–10 animals per 
treatment. The chimera vaccine induced the highest IgA response (a,B). The IgM antibodies were equally enhanced by the F3 and the chimera vaccines before 
challenge and by the F3 vaccine after challenge (c,D).
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resUlTs
The F1F3 chimera Optimizes the antibody 
response
We investigated, for all variables, if the vaccine containing the 
mixture of the F1 and F3 domains (F1 + F3) was more potent than 
the F1 and F3 vaccines independently. Our strategy also involved 
the use of the chimera at the dosage of 100 µg, in order to make 
a fair comparison with the simple addition of the two domains 
(F1 + F3), since both vaccines are composed of approximately 
50 µg of each F1 and F3 proteins. Additionally, we also used the 
chimera at the dosage of 200 µg, to disclose any potential dose–
response effect of increased efficacy determined by a higher dose 
of the antigen.
Initially, we compared the antibody response generated by 
the vaccines, both after complete immunization and after chal-
lenge by L. amazonensis (Figures 1 and 2). In contrast to what 
observed for the IgM antibodies (Figures 1C,D), the F1 protein 
alone did not induce any anti-NH36 antibodies of the IgG class or 
subclasses. The F3 vaccine on the other hand enhanced the IgM 
and all IgG antibodies against NH36 above the saline controls 
(p < 0.0001 for all comparisons) (Figures 1C,D and 2A–F). The 
IgM antibodies were equally enhanced by the F3 and the chimera 
vaccines before challenge and by the F3 vaccine after challenge 
(Figure 1).
Furthermore, the admixed domains induced more IgG, IgG1, 
and IgG2a antibodies than the F3 or the F1 vaccines did indepen-
dently (p < 0.007 for both) indicating that the administration of 
both proteins simultaneously potentiates the effect (Figures 1A,B 
and 2).
Remarkably, the chimera vaccine optimized the antibody 
response by inducing the highest IgA, IgG, and IgG2a anti-NH36 
responses (Figures  1A,B and 2A–C,E,F). In fact, the dose of 
200 µg determined additional increases of 19%, in the absorbency 
values, above those of the F1 + F3 and chimera (100 µg) vaccines 
(p < 0.0001 for both) revealing maximal optimization of the IgG 
response (Figure  2A). The 200 μg F1F3 chimera was also the 
strongest formulation for the IgG class after challenge (p < 0.0148 
for all comparisons) (Figure  2B) while the admixed proteins 
(F1 + F3) were no longer superior to the F3 vaccine.
Noteworthy and in agreement with what described for the IgG 
response, after immunization, the chimeras induced the most 
potent and optimized IgG2a response (Figure 2E). The dosage 
of 100 µg exhibited an increase of 20% (p < 0.0001) in the IgG2a 
antibody titers, above the F1 +  F3 vaccine, indicating that the 
presentation of the epitopes in tandem increases the efficacy. 
Additionally, and similar to what described for IgG (Figure 1A), 
the maximal IgG2a antibody response was induced by the 200 μg 
chimera vaccine, which promoted a 19% higher IgG2a response 
than the same vaccine at 100 μg dosage (p < 0.0001), indicating 
FigUre 2 | chimera increased the igg, igg1, and igg2a antibody levels. Anti-NH36 antibodies were measured by an ELISA assay in the sera of mice 
vaccinated with F1, F3, the addition of F1 and F3, or the F1F3 chimera in formulation with saponin and after infection with Leishmania amazonensis. Data are means 
and individual results of two independent experiments, each one with 8–10 animals per treatment. The F1 protein alone did not induce any increase in IgG, IgG1, or 
IgG2a antibodies while the F3 did (a–F). The mixture of domains enhanced the IgG, IgG1, and IgG2a antibody responses above the F3 and F1 proteins (a–D,F). 
The chimera, however, induced the strongest IgG and IgG2a anti-NH36 responses (a–c,e,F) being, at the dosage of 100 µg, more potent that the domain mixture 
(e,F), and at the dosage of 200 µg, stronger than at the dosage of 100 µg (a,B,e).
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a dose–response effect (Figure 2E). Optimization of the IgG2a 
antibody response was also detected as a result of the impact of 
L. amazonensis infection when the two chimera-vaccine dosages 
showed a 28% increased potency above the F1 +  F3 vaccine 
(p < 0.007 for the two comparisons) (Figure 2F).
For the IgG1 subtype, the admixed domains were as potent as 
the chimera (100 µg) (Figures 2C,D).
We concluded that the presentation of the F1 and F3 proteins 
in a recombinant chimera determined a stronger effect than 
the simultaneous delivery of both independent domains, for 
the induction of IgA, IgG, and IgG2a anti-NH36 antibodies. 
An increasing dose–response was additionally detected for the 
chimera in the IgG (before and after challenge) and IgG2a (before 
challenge) antibodies. In contrast, the chimera at the dosage of 
100  µg was even more potent than at 200  µg, for the IgA and 
IgM (before and after challenge) and IgG1 (after immunization) 
antibodies, and was as strong as at 200 µg dosage, for the IgG1 
and IgG2a (after challenge) response. These results suggest that 
the optimization effect is more related to the concomitant pres-
entation of the F1 and F3 epitopes in tandem, rather than to an 
increased antigen concentration.
The F1F3 chimera Optimizes the 
intradermal response to L. amazonensis 
antigen
The induction a cellular immune response was initially assessed 
by IDR. At all times, all formulations developed more potent IDR 
reactions that the saline controls and the F1 vaccine (p < 0.0001 
for all comparisons) (Figures  3A–D). Maximal skin tests were 
achieved in mice vaccinated with the chimera (Figure 3).
Although the chimera at 100 µg dosage was more potent than 
the admixed proteins (Figures  3A,B,D), and the F3 vaccine 
(Figure 3D), the dosage of 200 µg was the strongest formulation, 
which induced the largest skin tests (Figures 3A–D). In fact, at 
FigUre 3 | chimera optimizes the intradermal response against Leishmania amazonensis antigen. The IDR to the lysate of L. amazonensis infective 
promastigotes was measured in mice vaccinated with F1, F3, the addition of F1 and F3 proteins, or the F1F3 chimera, in formulation with saponin, after vaccination 
(a,c) and on week 12 after challenge with L. amazonensis (B,D), at 24 and 48 h after antigen injection. Data are means and individual results of two independent 
experiments, each one with 8–10 animals per treatment. All formulations were more potent than the saline controls and the F1 vaccine (a–D). The chimera, at 
100 µg dosage, was more potent than the addition of domains (a,B,D), and the F3 vaccine (D), but the dosage of 200 µg was the strongest formulation (a–D). 
After challenge (B,D) and 48 h after antigen injection (c,D), all vaccines enhanced the skin tests.
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the dosage of 100 µg, the chimera was already 13% more potent 
than the addition of F1 +  F3 proteins (p <  0.0232) disclosing 
the optimization effect that was due to the presentation of the 
epitopes in tandem. The additional 13% (p < 0.0263) enhance-
ment generated by the 200 µg dosage disclosed a dose–response 
effect (Figure 3A).
After challenge, and in contrast to what described for anti-
bodies, all the vaccines induced significant increases of skin tests 
(p < 0.0001). Actually, after infection, the skin tests of mice vac-
cinated with the F3, F1 + F3, 100, and 200 µg chimera vaccines 
were 47, 52, 53, and 51% larger than before challenge, respectively 
(p < 0.0001, for all comparisons) (Figures 3A,B). At 48 h after 
antigen injection also, respective IDR increases of 44, 38, 44, and 
38% were also observed for the F3, F1 + F3, 100, and 200 µg chi-
mera vaccines (p < 0.0001 for all comparisons) (Figures 3C,D).
Our results disclosed the chimera at the 200  µg dosage as 
the strongest formulation. However, at the dosage of 100 µg, the 
chimera was already capable of inducing the most pronounced 
enhancement of skin tests after infection, being even more 
efficacious that the admixed domains. These results confirm 
the chimera capability for optimization of vaccine efficacy and 
suggest that efficacy could be even enhanced by using increased 
chimera dosages (Figures 3A–D).
The IDR response after immunization is highly correlated to 
the IgG (p <  0.0001, R =  0.7552, R2 =  0.5703) and the IgG2a 
(p < 0.0001, R = 0.8839, R2 = 0.7813) antibody responses. Also, 
after infection, the IgG (p < 0.0001, R = 0.7009, R2 = 0.4912) and 
IgG2a antibody levels (p < 0.0001, R = 0.8364, R2 = 0.6995) were 
correlated to the IDR results.
secretion of iFn-γ, TnF-α, and il-10 
increased in response to the F1F3 
chimera
After immunization, all vaccines increased the IFN-γ secre-
tion to PBMC supernatants above the levels induced by the 
saline controls (p < 0.0022), indicating the triggering of a Th1-
immune response. Mice vaccinated with F3-containing vaccines 
secreted more IFN-γ than those treated only with the F1 protein 
(p < 0.0022). The main performance was, however, determined 
by the chimera at 100 µg dosage, which was 19% stronger than the 
admixed domains and 20% more potent than the 200 µg dosage 
(p < 0.0022 for both comparisons) (Figure 4A). After infection, 
and as observed for skin tests and IgG2a antibodies, the two 
dosages of the chimera showed codominance of the IFN-γ secre-
tion (Figure  4B) above the F1 and F3 vaccines independently 
or formulated together (p < 0.0002 for all comparisons). IFN-γ 
levels induced by the chimeras after challenge were 56–44% lower 
(Figure 4B).
As observed for IFN-γ and also indicating the rise of a Th1 
response, TNF-α was initially more secreted by mice vaccinated 
with F3 than with F1 (p < 0.0022) (Figure 4C) and by all vaccines 
FigUre 4 | chimera potentiates the secretion of iFn-γ and il-10 while TnF-α is generated in response to all F3-containing vaccines. Secretions of 
IFN-γ (a,B), TNF-α (c,D), and IL-10 (e,F), as measured by an ELISA assay in the supernatant of splenocytes, both after immunization with F1, F3, the addition of 
F1 and F3 proteins, or the F1F3 chimera in formulation with saponin, and after challenge with Leishmania amazonensis, are expressed in picograms per milliliter. 
Data are means and individual results of two independent experiments, each one with 8–10 animals per treatment. After immunization, the F3-containing vaccines 
secreted more IFN-γ than the F1 vaccine. The chimera at 100 µg dosage was stronger than the admixed proteins and the 200 µg dosage (a). After infection, the 
two dosages of the chimera were equally potent (B) above the F1 and F3 vaccines independently or formulated together. However, the IFN-γ levels after challenge 
were lower (B). TNF-α was initially more secreted by mice vaccinated with F3 than with F1 (c) and by all vaccines containing the F3 domain, after challenge (D). The 
chimeras or the admixed proteins enhanced IL-10 secretion after immunization, above the F1 or F3 vaccines (e). After challenge, IL-10 secretion was null in 
F3-vaccinated mice, but it was increased by the other vaccines with maximal performance achieved by the chimera (200 µg) (F). A dose–response increase in IFN-γ 
(B) and IL-10 (F) secretion was observed with the increment of the chimera dosage.
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containing the F3 domain, including the chimeras, after challenge 
(Figure 4D).
Additionally and suggesting a potential regulatory immune 
response, mice vaccinated with the chimeras or with the admixed 
proteins secreted more IL-10 after immunization than mice 
vaccinated with F1 or F3 proteins alone (p < 0.015 for all com-
parisons) (Figure 4E). Noteworthy, IL-10 secretion was higher in 
mice vaccinated with 100 µg of the chimera than with the F1 + F3 
addition, both before and after challenge (Figures 4E,F).
Remarkably, after challenge, however, IL-10 secretion was 
null only in F3-vaccinated mice while it was increased by all 
vaccines containing F1 and achieved the maximal values in the 
200 μg chimera vaccine (Figure 4F). In fact, after infection, the 
IL-10 levels were 2.3 times reduced (p < 0.0007) in F3-vaccinated 
mice, while increases of 2.6 (p < 0.0007), 1.4 (p < 0.0200), 1.5 
(p < 0.0023), and 2.3 times (p < 0.0007) were detected in mice 
vaccinated with the F1, F1 + F3, and the chimera vaccine at 100 
and 200 µg dosage, respectively (Figures 4E,F).
Lastly, a dose–response increase in IFN-γ and IL-10 secre-
tion was observed with the increment of the chimera dosage to 
200 µg.
The F1F3 chimera induces the highest 
Proportions of cD4+ and cD8+ T cells 
secreting One, any combination of Two 
and Three cytokines
The effector function and quality of the T cell immune response 
were assessed after infection, by multiparameter-flow cytometry 
analysis.
The chimera vaccine at 100  μg/dose induced the highest 
proportions of all types of CD4+-cytokine secreting T cells 
(Figure  5). In fact, the 100 μg/dose chimera was more potent 
than the F3 (p <  0.0469) and F1 +  F3 vaccines (p <  0.0391) 
inducing elevated proportions of CD4+ T cells secreting IL-2, 
TNF-α, or IFN-γ alone (Figures 5A–C), TNF-α in combination 
FigUre 5 | chimera and F1 vaccines promote the highest proportions of cD4+ T cells expressing one cytokine, all combinations of two cytokines, 
or three cytokines after in vitro incubation with nh36. The multifunctional analysis discloses the magnitude of the CD4+ T-cell response of mice immunized 
and challenged with Leishmania amazonensis, by describing the contribution of the frequencies of CD4+ lymphocytes expressing IL-2 (a), TNF-α (B), IFN-γ (c), 
IL-2/TNF-α (D), TNF-α/IFN-γ (e), IL-2/IFN-γ TNF-α/IFN-γ (F), and IL-2/TNF-α/IFN-γ TNF-α/IFN-γ (g) in response to NH36. Bars represent means + SE of two 
independent experiments, each one with 8–10 animals per treatment. The chimera vaccine at 100 μg/dose induced the highest proportions of all types of 
CD4+-cytokine secreting T cells (a–e,g). It was stronger than the 200 µg dosage and not significantly different from the F1 vaccine (a–c,e,g) for all CD4 T cells 
subtypes, except for CD4+-TNF-α+-IL-2+ (c,D). Only in the case of CD4+-IL-2+-IFN-γ+ T cells, the differences between the vaccines were no significant (F).
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with IL-2 or IFN-γ (Figures  5D,E) and multifunctional cells 
secreting IL-2, TNF-α, and IFN-γ simultaneously (Figure 5G). 
Additionally, the 100 µg dose was stronger than the 200 µg dos-
age (p < 0.0391) and not significantly different than the F1 vac-
cine (Figures 5A–C,E,G) for all CD4 T cells subtypes, except for 
CD4+-TNF-α+-IL-2+ (Figures 5C,D). Our results indicate the 
presence of important CD4+ epitopes in F1 (Figures 5A–E,G) 
and suggest that the presentation of the epitopes in tandem by 
the chimera represents the best approach for optimization of 
the Th1 response. Only in the case of CD4+-IL-2+-IFN-γ+ T 
cells, the differences between the vaccines were no significant 
(Figure 5F).
Regarding the cytotoxic response (Figure  6), the admixed 
proteins were not capable of inducing higher CD8+ T cell pro-
portions than the F1 or F3 domains independently (Figure 6). 
Furthermore, as described for CD4+ T cells (Figure  5), the 
chimera vaccine, at the dosage of 100  µg, also promoted the 
highest proportions of CD8+ T cell expressing IL-2, TNF-α, or 
IFN-γ (Figures 6A–C) and TNF-α, in combination with IL-2 or 
IFN-γ (Figures 6D,E). This did not occur for the CD8+ multi-
functional T cells which, in contrast to what observed for CD4+ 
T cells, showed no significant differences between treatments 
(Figures 6F,G).
At 100  µg dosage, the chimera was more potent than at 
200  µg for the increase of the proportions of CD8+-TNF-α+ 
(p < 0.0078) and CD8+-IFN-γ+ secreting T cells (p < 0.0078). 
Additionally, and similar to what described for CD4+ T cells 
(Figure 5), the 100 µg chimera vaccine was stronger than the F3 
vaccine in CD8+-TNF-α+-IFN-γ T cells and as potent as the F1 
vaccine in induction of most types of CD8+-cytokine secreting 
T cells (Figures 6A,B,D,E), except for cells secreting only IFN-γ 
(Figure 6C). Our results also indicate that important epitopes for 
CD8+ T cells are located in the F1 domain.
The multifunctional flow cytometry confirmed that in order 
to optimize the antigen presentation to T cells, the exposure of 
the F1 and F3 domains cloned in tandem is needed. The simple 
addition of the two domains was not effective in triggering the 
cellular immune response. We conclude that the chimera at the 
dosage of 100 µg generated the strongest protection against the 
parasite challenge but was not significantly different from the F1 
vaccine.
Vaccine efficacy is Optimized by the F1F3 
chimera Formulation
The evolution of the infection was monitored by the increase 
of the skin lesion sizes up to week 12 after infection. The linear 
regression analysis revealed significantly different degrees 
of vaccine-induced protection disclosed by the decreased 
slopes of their respective curves: 0.3033 ±  0.016 for the F1, 
0.2257 ±  0.012 for the F3, 0.1973 ±  0.009 for the F1 +  F3, 
0.1793 ±  0.008 for the F1F3 100  µg, and 0.1640 ±  0.007 for 
FigUre 6 | chimera and F1 vaccines generate the highest proportions of cD8+ T cells expressing one cytokine, all combinations of two cytokines, 
or three cytokines after in vitro incubation with nh36. The magnitude of the cytotoxic T-cell response is revealed by the cytometry-multifunctional analysis, 
which disclosed the frequencies of CD8+ lymphocytes expressing IL-2 (a), TNF-α (B), IFN-γ (c), IL-2/TNF-α (D), TNF-α/IFN-γ (e), IL-2/IFN-γ TNF-α/IFN-γ (F), and 
IL-2/TNF-α/IFN-γ TNF-α/IFN-γ (g) in response to NH36, of mice vaccinated with F1, F3, the addition of F1 and F3, or the F1F3 chimera and challenged with 
Leishmania amazonensis. Bars represent means + SE of two independent experiments, each one with 8–10 animals per treatment. The admixed proteins were not 
capable of inducing higher CD8+ T cell proportions than the F1 or F3 vaccines. The chimera vaccine (100 µg) promoted the highest proportions of CD8+ T cell 
expressing all combination of cytokines (a–e) except for the CD8+ multifunctional T cells (g) and was more potent than at 200 µg for the increase of the 
proportions of CD8+-TNF-α+ (B) and CD8+-IFN-γ+ secreting T cells (c). The 100 µg chimera vaccine was also stronger than the F3 vaccine in CD8+-TNF-α+-IFN-
γ T cells and as potent as the F1 vaccine in induction of most types of CD8+-cytokine secreting T cells (a,B,D,e).
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the F1F3 200 µg vaccines. Except for the F1 vaccine, all formu-
lations induced protection and decreased the lesion sizes in 
comparison to saline controls (p < 0.0351 for all comparisons) 
(Figure 7A). Furthermore, the F1 + F3 vaccine and the chi-
meras were more efficacious than the F1 vaccine (p < 0.0500) 
(Figure 7A) and equally potent until week 8 after infection. By 
the end of the experiment, on week 12, however, the strongest 
reduction in lesion sizes was determined by the combination 
of F1 + F3 domains and by the chimera, at the 100 and 200 µg 
dosages, which induced 80, 82, and 84% of protection, respec-
tively (Figure 7A).
Additionally, the parasite load was evaluated after eutha-
nasia by a limiting dilution assay on week 12 after infection 
(Figure  7B). While the saline controls exhibited 1,259,770 
promastigotes, the chimera vaccines at 100 μg/dose decreased 
the parasite load to 2,423 (p <  0.0040) and at 200  μg/dose, 
to 1,424 (p <  0.0062). Our results indicate that the presenta-
tion of epitopes in tandem in a recombinant chimera exceeds 
the protection generated by the mixture of the recombinant 
domains F1 and F3. In fact, efficacies of 99.8 and 99.9% were 
achieved using the chimera at 100 and 200 μg/dose, respectively. 
The measures of footpad lesions at week 12 after infection and 
the log10 number of parasites in lesions were highly correlated 
(p < 0.001, R = 0.5640, R2 = 0.3181).
The increases in the antibody response were good surrogates 
for protection. In fact, we detected significant negative cor-
relations between the increase of all antibody subtypes and the 
decrease of footpad lesion sizes and of the number of parasites. 
The IgG2a increase for instance was negatively correlated to 
the size of footpad lesions (p < 0.0001, R = −0.6026 before and 
p =  0.0029, R = −0.4246 after infection) and to the number 
of parasites in lesions (p  =  0.0293, R  =  −0.3147 before and 
p = 0.0031, R = −0.4177 after infection).
Additionally, the IDR (p <  0.0001, R = −0.7815) and the 
frequencies of multifunctional CD4+ (p < 0.0500, R = −0.2803) 
and CD8+ T cells (p <  0.0001, R = −0.7837) expressing IL-2, 
TNF-α, and IFN-γ, after infection, were strong correlates of pro-
phylactic efficacy. In agreement to that, the number of parasites 
in lesions was also negatively correlated with the IDR (p = 0.0012, 
R = −0.4531) and the CD8 T cells expressing IL-2, TNF-α, and 
IFN-γ (p = 0.0012, R = −0.4531).
We conclude that vaccination with the F1F3 chimera opti-
mizes the cross-species vaccine efficacy against L. amazonensis 
infection above the levels reached by the admixed domains.
TaBle 1 | iFn-γ/il-10 and TnF-α/il-10 ratios secreted in response to the 









0219-40 CD4 F1 ELLAITTVVGNQ 0.18 0.81
54-68 CD4 F1 DVAGIVGVPVAAGCT 0.14 0.59
92-100 CD8 F1 YPPEFKTKL 0.96 0.49
217-230 CD4 F3 FMLQILDFYTKVYE 0.64 0.60
278-291 CD4 F3 FRYPRPKHCHTQ 0.92 1.72
298-311 CD4 F3 KFWCLVIDALKRIG 0.29 1.00
aThe in silico predicted epitopes for CD4+ and CD8+ lymphocytes of Balb/c mice were 
previously described by Nico et al. (17).
FigUre 7 | chimera optimized the vaccine efficacy by inducing the 
strongest reductions in sizes and parasite load of the skin lesions. 
BALB/c mice were immunized with three subcutaneous doses of F1, F3, F1 
and F3 (F1 + F3), or F1F3 chimera (100 or 200 µg) formulated in saponin and 
were challenged with Leishmania amazonensis. The evolution of footpad 
lesion sizes was weekly monitored with a pachymeter (a). The values of the 
infected right hind-footpads were discounted from those of the contra-lateral 
left hind-footpads injected with saline. The parasite load in the skin lesion 
was measured after euthanasia by a limiting dilution assay on day 4 after 
in vitro culture (B). Data represent means (a) and means + SE (B) of two 
independent experiments, each one of them with 8–10 animals per 
treatment. Except for the F1 vaccine, all formulations induced protection and 
decreased the lesion sizes in comparison to saline controls (linear regression 
analysis) (a). The F1 + F3 vaccine and the chimeras were stronger than the 
F1 vaccine but, on week 12, however, the strongest reductions in lesion sizes 
were determined by the combination of F1 + F3 domains (80%) and by 
chimera at the 100 µg (82%) and 200 µg (84%) dosages (a). The parasite 
load, on the other hand, revealed efficacies of 99.8 and 99.9% developed by 
the chimeras at 100 and 200 μg/dose, respectively (B).
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cD4+ and cD8+ T-cell epitopes of the F1 
and F3 Domains exceed the cellular 
immune response generated by the 
chimera
Toward the design of a potential synthetic vaccine, we further 
investigated which of the predicted F1 and F3 domains’ T-cell 
epitopes target the optimized cellular immune response and 
induce in vitro T cell responses even stronger than the chimera.
The in  silico prediction for CD4+ T cell epitopes per-
formed before (17) mapped two sequences of CD4+ T cell 
epitopes of BALB/c mice in F1 (ELLAITTVVGNQ and 
DVAGIVGVPVAAGCT) and three more sequences in the F3 
domain (FMLQILDFYTKVYE, FRYPRPKHCHTQVA, and 
KFWCLVIDALKRIG) (Table 1). Additionally, the highest scored 
CD8+ epitope (YPPEFKTKL) of the NH36 protein was identified 
in the F1 domain (17) (Table 1). We here compared the secretion 
of cytokines induced by each one of these epitopes alone or 
mixed together, using the NH36 and F1F3 chimera antigens as 
controls, in mice vaccinated with the chimera, on week 11 after 
L. amazonensis challenge.
Actually, several epitopes induced higher cytokine secre-
tion than the NH36 and their chimera cognate proteins in 
vaccinated mice and that their controls in saline treated mice. 
Among them, remarkably, the YPPEFKTKL epitope of F1 and 
the FMLQILDFYTKVYE epitope of the F3 domain promoted 
the highest levels of IFN-γ (Figure  8A), and together with 
ELLAITTVVGNQ and DVAGIVGVPVAAGCT epitopes, 
also the strongest secretion of TNF-α (Figure  8B) and IL-10 
(Figure 8C).
In contrast, the two other CD4+ predicted epitopes of F3, 
FRYPRPKHCHTQVA and KFWCLVIDALKRIG, induced a 
moderate but significant secretion of TNF-α (Figure 8B) and no 
secretion or poor levels of IL-10 (Figure 8C), respectively, when 
compared to the untreated saline controls.
These results suggested the induction of a mixed Th1/Th2 
immunity in response to the FMLQILDFYTKVYE of F3, and the 
YPPEFKTKL, ELLAITTVVGNQ, and DVAGIVGVPVAAGCT 
predicted epitopes of the F1 domain. In contrast, the two final 
CD4 predicted epitopes of F3, FRYPRPKHCHTQVA and 
KFWCLVIDALKRIG generated a main Th1 response, with a pre-
dominant TNF-α production and low IL-10 secretion (Figure 8).
Calculation of the IFN-γ/IL-10 and TNF-α/IL-10 secreted 
ratios confirmed the generation of the Th1 response (Table 1). 
In fact, the FRYPRPKHCHTQVA sequence of F3 induced an 
elevated IFN-γ/IL-10 and the highest TNF-α/IL-10 ratio. The 
KFWCLVIDALKRIG epitope also generated a high TNF-α/IL-10 
ratio, which was followed by the ELLAITTVVGNQ sequence. 
Interestingly, the YPPEFKTKL epitope also promoted a high 
IFN-γ/IL-10 ratio (Table 1).
The multiparameter cytometry analysis disclosed that the 
FRYPRPKHCHTQVA epitope as the most potent enhancer 
of the CD4+-TNF-α, -IFN-γ, -TNF-α-IL-2, -TNF-α-IFN-γ 
and -IFN-γ-IL-2 T cell proportions (Figure  9), confirming its 
capability of raising a specific Th1 response (Figures 8B,C). The 
YPPEFKTKL epitope was the second most important sequence 
which, although predicted as a CD8 epitope, also stimulated the 
increase of the proportions of CD4+ T cells producing TNF-α, 
IFN-γ, IL-2-IFN-γ and TNF-α-IFN-γ, as much as the chimera 
did (Figure  9). Additionally, the multifunctional IL-2-TNF-α-
IFN-γ-secreting CD4+ T-cells were only raised in response to the 
FigUre 8 | The YPPeFKTKl and FMlQilDFYTKVYYe epitopes promote the highest iFn-γ and il-10 levels, and together with DVagiVgVPVaagcT 
and ellaiTTVVgnQ, the strongest TnF-α secretion of splenocytes of chimera-vaccinated mice. Splenocytes of mice vaccinated with 100 µg of the 
chimera were incubated in vitro with 10 µg/ml of NH36, F1F3 chimera, each one of the CD4 predicted epitopes of F1 (ELLAITTVVGNQ and DVAGIVGVPVAAGCT) 
and F3 domains (FMLQILDFYTKVYE, FRYPRPKHCCHTQVA, and KFWCLVIDALKRIG) and with the highest scored CD8 predicted epitope of the F1 protein 
(YPPEKTKL), or with the mixture of all the epitopes, at week 11 after infection. Secretions of IFN-γ (a), TNF-α (B), and IL-10 (c) were measured by an ELISA assay 
in the supernatants of splenocytes and expressed in picograms per milliliter. Data are means + SE of two independent experiments, each one with 8–10 animals per 
treatment. The YPPEFKTKL epitope of F1 and the FMLQILDFYTKVYE epitope of the F3 domain promoted the highest levels of IFN-γ (a), and together with 
ELLAITTVVGNQ and DVAGIVGVPVAAGCT epitopes, also the strongest secretion of TNF-α (B) and IL-10 (c). In contrast, the FRYPRPKHCHTQVA and 
KFWCLVIDALKRIG of F3 induced a moderate but significant secretion of TNF-α (B) and no secretion or poor levels of IL-10 (c).
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FRYPRPKHCHTQVA, FMLQILDFYTKVYE, and the admixed 
epitopes. In contrast, no epitope increased the percent of CD4+ T 
cells secreting only IL-2 above the levels promoted by the chimera 
(Figure 9).
Regarding the cytotoxic response, YPPEFKTKL was the 
most potent epitope. Alone, it induced higher proportions of 
CD8+ T cells secreting IFN-γ and IFN-γ in combination with 
IL-2 than the chimera; together with DVAGIVGVPAAGCT and 
KFWCLVIDALKRIG, the highest frequencies of CD8+-IL-2+ 
T cells and combined only with DVAGIVGVPAAGCT, the 
highest proportions of CD8+-TNF-α+-IFN-γ+ T cells. 
Furthermore, DVAGIVGVPAAGCT was the only epitope 
to increase the frequencies of CD8+-TNF-α+-IL-2+ T cells 
(Figure  10). In contrast, the cytotoxic T cells secreting only 
TNF-α were increased in response to the ELLAITTVVGNQ 
and the FMLQILDFYTKVYE epitopes (Figure 10).
DiscUssiOn
NH36 is an important phylogenetic marker, highly conserved 
among the species of the Leishmania genus. Thus, it became a 
strong candidate antigen for the development of a bivalent cross-
protective vaccine against both visceral and CL (17, 28, 29, 38). 
We previously demonstrated that the F3 protein of NH36 hosts 
FigUre 9 | Multiparameter cytometry analysis disclosed that the FrYPrPKhchTQVa followed by the YPPeFKTKl epitopes induced the most 
potent cD4+ T cell response. Splenocytes of chimera-vaccinated mice were incubated with NH36, the chimera, the ELLAITTVVGNQ, DVAGIVGVPVAAGCT, 
YPPEKTKL, FMLQILDFYTKVYE, FRYPRPKHCCHTQVA, and KFWCLVIDALKRIG sequences, or with the mixture of all the epitopes, at week 11 after infection. The 
magnitude of the CD4+ T cell response was disclosed by the frequencies of the CD4+ lymphocytes expressing IL-2 (a), TNF-α (B), IFN-γ (c), IL-2/TNF-α (D), 
TNF-α/IFN-γ (e), IL-2/IFN-γ TNF-α/IFN-γ (F), and IL-2/TNF-α/IFN-γ TNF-α/IFN-γ (g) in response to each antigen. Bars represent means + SE of two independent 
experiments, each one with 8–10 animals per treatment. The FRYPRPKHCHTQVA epitope induced maximal CD4+-TNF-α, -IFN-γ, -TNF-α-IL-2, -TNF-α-IFN-γ, and 
-IFN-γ-IL-2 T cell proportions, confirming its capability of raising a specific Th1 response. The YPPEFKTKL epitope was the second most important sequence to 
enhance the proportions of CD4+ T cells producing TNF-α, IFN-γ, IL-2-IFN-γ, and TNF-α-IFN-γ. The IL-2-TNF-α-IFN-γ-secreting CD4+ T-cells were only raised in 
response to the FRYPRPKHCHTQVA, FMLQILDFYTKVYE, and the admixed epitopes. In contrast, the chimera promoted the strongest CD4+-IL-2 T cell response.
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the immunodominant CD4+ epitopes necessary for protection 
against L. chagasi (17) and L. amazonensis (17, 28) infections. 
Instead, the F1 protein codominance with F3, in protection 
against L. amazonensis infection, is mediated mostly by CD8+ 
epitopes (28). Accordingly, the highest scored epitope for CD8+ 
T cells, YPPEFKTKL, was identified in the sequence of the F1 
protein (17). The finding of 93% sequence homology between 
the NH36 of L. donovani and the A34480 NH of L. amazonensis 
encouraged even more the idea of a NH-based bivalent vaccine 
against both leishmaniasis (28).
According to the philosophy of the T cell polytope vaccine 
development, efficacy increases using antigens that contain 
enriched proportions of the relevant epitopes (34, 35). Searching 
for the optimization of the vaccine efficacy against L. amazonensis 
infection, in this investigation, we used the F1 and F3 domains 
of NH36 through several approaches. First, we investigated if 
the simple mixture of F1 and F3 vaccines increased the efficacy 
above the levels induced by the F1 and F3 vaccines independently. 
Second, we asked if the presentation of F1 and F3 domains cloned 
in tandem, as a chimera, was more efficacious than the presenta-
tion of the admixed proteins. Third, we assayed if the chimera-
induced protection could be enhanced in a dose–response manner 
by doubling the vaccine concentration. Finally, we identified the 
most important epitopes for CD4+ and CD8+ T cells included in 
the chimera that could be combined in a future synthetic polytope 
vaccine capable to induce cross-protection to CL.
Confirming that the F3 and F1 domains contain the epitopes 
responsible for the NH36-induced immune protection, higher 
efficacy was obtained by vaccination with each one of these 
proteins rather than with the whole NH36 cognate protein 
(17, 28, 29, 33). Additionally, the cross-protective capabilities 
of the NH36 vaccines can be explained by the high identity 
of the sequences of predicted epitopes of the two Leishmania 
NHs (28). In fact, the CD4+ epitope ELLAITTVVGNQ and 
the CD8+ epitope YPPEFKTKL of the F1 domain of NH36 
(17) are completely conserved in the sequence of NH A34480 
of L. amazonensis (28). Likewise, the DVAGIVGVPVAAGCT 
epitope for CD4+ T cells of F1, and the three epitopes for CD4+ 
FigUre 10 | Multiparameter cytometry analysis disclosed that the YPPeFKTKl followed by the DVagiVgVPVaagcT, FMlQilDFYTKVYe, and 
ellaiTTVVgnQ epitopes induced the most potent cD8+ T cell response. Splenocytes of chimera-vaccinated mice were incubated with NH36, the chimera, 
the ELLAITTVVGNQ, DVAGIVGVPVAAGCT, YPPEKTKL, FMLQILDFYTKVYE, FRYPRPKHCCHTQVA, and KFWCLVIDALKRIG sequences, or with the mixture of all 
the epitopes, at week 11 after infection. The magnitude of the CD4+ T cell response was disclosed by the frequencies of the CD4+ lymphocytes expressing IL-2 
(a), TNF-α (B), IFN-γ (c), IL-2/TNF-α (D), TNF-α/IFN-γ (e), IL-2/IFN-γ TNF-α/IFN-γ (F), and IL-2/TNF-α/IFN-γ TNF-α/IFN-γ (g) in response to each antigen. Bars 
represent means + SE of two independent experiments, each one with 8–10 animals per treatment. YPPEFKTKL was the most potent epitope. Alone, it induced 
higher proportions of CD8+ T cells secreting IFN-γ and IFN-γ in combination with IL-2 than the chimera; together with DVAGIVGVPAAGCT and KFWCLVIDALKRIG, 
the highest frequencies of CD8+-IL-2 T cells and combined only with DVAGIVGVPAAGCT, the highest proportions of CD8+-TNF-α-IFN-γ T cells. In addition, 
DVAGIVGVPAAGCT increased the frequencies of CD8+-TNF-α-IL-2 T cells. In contrast, ELLAITTVVGNQ and the FMLQILDFYTKVYE epitopes increased the 
frequencies of T cells secreting only TNF-α.
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T cells of F3, FMLQILDFYTKVYE, FRYPRPKHCHTQVA, and 
KFWCLVIDALKRIG differ in only one amino acid (28).
Strong IgG1, IgG2a, and/or IgG2b anti-NH36 antibody 
responses were described after mice vaccination with the gene of 
NH36 (23, 24, 27), with the NH36 recombinant protein in com-
bination with saponin (17, 28, 29), CPG and polylactil glycolide 
particles (39), and the GLA-SE adjuvant (40), or with the NH36 
cloned with a sterol 24-C-methyl transferase (NS), and used with 
GLA-SE adjuvant (30). Furthermore, higher IgG2/IgG1 antibody 
ratios were also found after immunotherapy of Leishmania infan-
tum chagasi-infected dogs with NH36-DNA (25). Additionally, 
human vaccination with NS determined a preferential increase 
in IgG1 and IgG3 subclasses, which are dependent of Th1-like 
cytokines (30).
Vaccination with F3, but not with F1, induced higher IgG2a 
antibody levels than NH36, in mice challenged with L. chagasi 
(17). In contrast, IgG2a, IgG1 antibody levels were similar in mice 
challenged with L. amazonensis (28, 29). Although protection 
against leishmaniasis depends more, on the cellular than on the 
humoral immune response, it is worth to note that these increased 
antibody subtypes are strong surrogates predictive of protection 
(41), which indicate the decrease of parasite load (17, 28, 29) and 
that could also be the basis of the development of a transmission 
blocking vaccine (38, 42).
We previously identified in the F3 domain, the epitopes 
AVQKRVKEVGTKPAAFML (202–219), VYEKERNTYATV 
(228–239), and FRYPRPKHCHTQVA (278–291), as the most 
relevant targets of the anti-NH36 antibody response in mice 
(17). Supporting our results, two B cell epitopes for dog and 
human antibodies were confirmed in the sequence of NH36 by 
other group (43). These epitopes, called peptide 17 and 18 (43), 
overlap with the sequences AVQKRVKEVGTKPAAFML and 
NQTLEKVTRNARLVADVAG that we previously described 
in the F3 and F1 domains, respectively (17). Interestingly, the 
peptide17 diagnosed with 100% sensitivity canine and human 
VL (43). These results disclose the universal nature of the B cell 
epitopes of NH36.
We further demonstrated that the admixed F1 + F3 vaccine 
induced more IgG, IgG1, and IgG2a antibodies than the F3 or 
the F1 vaccines did independently, suggesting a potentiated 
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immunogenicity. However, the presentation of the domains 
cloned in tandem as the chimera was superior and exceeded the 
IgG and IgG2a response above the admixed domains showing an 
additional dose–response effect.
Our results demonstrate that the delivery of the F1 and F3 
domains cloned in tandem, rather than as a simple mixture, 
increases the probabilities of a single antigen presenting cell to 
exhibit simultaneously both the CD8+ and CD4+ epitopes to 
lymphocytes, optimizing the immunogenicity. This might occur 
through cross-priming when MHC class II molecules can present 
both, exogenous molecules acquired by antigen presenting cells 
and endogenous degraded antigens (44, 45). Therefore, our 
results suggest that not only the composition of the epitopes and 
subunits is critical but also how the epitopes are exposed in the 
tridimensional structure of the vaccine antigen (46). In fact, only 
the tandem arrangement, but not the independent subunits con-
taining an HIV epitope represented the most efficient immuno-
genic conformation (46). Another advantage of the presentation 
of the epitopes in a recombinant chimera is that it facilitates the 
scaling-up of the antigen, reducing the production yield time and 
cost, when large amounts of antigen for clinical phase III and IV 
assays are needed.
Regarding the generation of the cellular immune response, the 
F3 domain induced stronger IDR than the F1 protein in mice 
vaccinated against L. chagasi (17) and L. amazonensis (28, 29). 
In this investigation, we showed that the admixed antigens were 
even better than F3, but also, that the chimera induced the strong-
est IDR after infection and an increased a dose–response effect. 
Supporting our previous descriptions (17, 28, 29), the IDR was 
an important correlate of protection that increased along with 
the decrease of parasite load, indicating the generation of a robust 
cellular immune response against L. amazonensis optimized by 
vaccination with the chimera.
We confirmed here our previous results showing that mice 
vaccinated with F3 and challenged with L. amazonensis increase 
the IFN-γ and TNF-α secretion but have a null IL-10 response 
(28, 29). Mice vaccinated with the F1 domain, on the other hand, 
secreted IFN-γ, TNF-α, and IL-10, suggesting the simultaneous 
stimulation of T reg subsets and the presence of epitopes for T 
regs along its sequence (28, 29). In this investigation, vaccina-
tion with the chimera induced a concomitant higher expression 
of IFN-γ and IL-10 than the admixed domains, and a dose–
response effect. This is remarkable considering that IL-10 has 
been shown to be related both to the pathology and the control 
of CL (47) and that IFN-γ has also a dual role, as inducer of 
effector mechanisms and, conversely, as a mediator of inflamma-
tion and pathogenesis (48). Increased CD4+ T cell proportions 
secreting IFN-γ with low proportions of CD4+-IL-4 T cells were 
also described in mice vaccinated with NH36 and challenged 
with L. mexicana (40).
We additionally demonstrated that the chimera vaccine at 
100 μg/dose induced the highest proportions of all types of CD4+ 
and CD8+ T cells secreting IL-2, TNF-α, or IFN-γ alone, TNF-α 
in combination with IL-2 or IFN-γ, and the highest percentage 
of CD4+ multifunctional cells secreting IL-2, TNF-α, and IFN-γ 
simultaneously. In fact, the chimera optimized the induction 
of a CD4+ Th1 immune response by promoting the highest 
proportions of CD4+ effector and long-term memory potential 
T cells, being the strongest vaccine at all the steps of the CD4 
T cell differentiation (36). Thus, and confirming the in  silico 
prediction (17) important epitopes for CD4+ T cells are present 
both in the F1 and F3 domains and their presentation in tandem, 
in the chimera, improve significantly their immunogenicity. This 
very desirable performance was observed also for the cytotoxic 
immune response. The highest proportions of all subtypes of 
CD8+-cytokine secreting T cells were observed in response to 
the chimera, except for the multifunctional cells. As detected for 
the CD4+ T cells, F1 was the second most important vaccine for 
the induction of the cytotoxic response while no enhancement 
was induced by the admixed antigens.
The immunotherapeutic effect induced by the F1 or F3 domains 
against L. amazonensis infection was predicted by the frequencies 
of the CD4+ and CD8+ T cells producing IL-2 or TNF-α or both 
(29). Total frequencies and frequencies of double-cytokine CD4 T 
cell producers were enhanced by F1 and F3 vaccines. In contrast 
to what described for prophylactic vaccination with the chimera, 
no increases in CD4+ multifunctional T cells were observed 
after immunotherapy with the independent domains (29). On 
the other, the F1 vaccine was codominant in prophylaxis with the 
chimera, for both CD4+ and CD8+ T cells (this investigation) 
and promoted the highest proportions of CD8+ multifunctional 
T cells when used for immunotherapy (29).
The reduction of parasite load and sizes of lesions confirmed 
the predictions of the immunological assays. Cross-protection 
to L. amazonensis infection was maximal (99.8–99.9%) in mice 
vaccinated with the chimera. As described before, and in spite of 
raising a strong CD4+ and CD8+ T cell immunogenic response, 
the F1 vaccine was less protective (17, 28).
We concluded that the chimera optimized the immune cross-
protection against L. amazonensis, above the levels induced by 
the F1 and F3 domains either admixed or independently. Our 
results indicated the development of a Th1-immune response 
mediated by CD4+ T cell epitopes of the F3 and F1 domains, 
a cytotoxic response induced by F1 and the potential presence 
of T reg epitopes in the F1 domain determining also a potential 
regulatory response. The three arms of immunity increased by 
the presentation of the F1 and F3 epitopes in tandem in the F1F3 
chimera.
Progressing toward the definition of a polytope vaccine, we 
were further able to identify the epitopes of NH36 responsible 
for the cross-protection against L. amazonensis infection. 
Confirming that they are the target of the immune response, 
some epitopes exceeded the levels of cytokine secretion induced 
by the chimera (33). The FMLQILDFYTKVYE and YPPEFKTKL 
sequences promoted, respectively, a 3.2- and 3.8-fold enhance in 
IFN-γ, a 3.2- and 2.9-fold increase in IL-10, and a 2.3- and 1.5-
fold augment of TNF-α secretion above the levels generated by 
the chimera.
Additionally, we further elucidated that the main Th1 
response induced by the NH36 and the chimera was due to 
the FRYPRPKHCHTQVA epitope of F3, which generated 
elevated IFN-γ/IL-10 and TNF-α/IL-10 ratios and the highest 
proportions of CD4+-TNF-α, -TNF-α-IL-2, -TNF-α-IFN-γ, 
-IFN-γ-IL-2, and multifunctional IL-2-TNF-α-IFN-γ T cells. 
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The FRYPRPKHCHTQVA epitope might be the reason for the 
CD4+ Th1 TNF-α-mediated protection induced by F3 and previ-
ously detected against both visceral (17) and CL in mice [(this 
investigation) (28, 29)]. In fact, only the FRYPRPKHCHTQVA 
sequence determined a high CD4+ response with strong IFN-γ, 
TNF-α secretion, and null IL-10 response, as already described 
for the F3 vaccine (17, 29).
Although first predicted as a CD8 epitope (17, 28), the 
YPPEFKTKL sequence of F1 also contributed to the CD4+ 
T cell response. In fact, it was the second most important 
CD4+-epitope, which stimulated a high IFN-γ/IL-10 ratio and 
increased proportions of CD4+ T cells producing TNF-α, IFN-γ, 
IL-2-IFN-γ, and TNF-α-IFN-γ. Additionally, the YPPEFKTKL 
and DVAGIVGVPAAGCT epitopes were the most important 
sequences inducing the CD8+ T cell response. Likewise, the 
ELLAITTVVGNQ and the FMLQILDFYTKVYE epitopes also 
induced elevated frequencies of CD8−TNF-α T cells, although 
they were predicted as CD4+ T cell epitopes of mice (17, 28). 
In agreement with that, the AFMLQILDF sequence was also 
predicted as a human epitope of CD8+ T cells binding the HLA-
A*2402 and HLA-B*4402, HLA-A*01 molecules (49).
We demonstrated that the YPPEFKTKL epitope capabilities 
of stimulating both the CD4+ and CD8+ T cell response, with 
intense production of pro-inflammatory cytokines, indicating 
its potential PAN epitope nature (50). YPPEFKTKL was the 
only predicted epitope for CD8+ T cells identified in the F1 
domain (17) and because of that, it is probably the responsible 
for the CD8− T cell mediate vaccine protection against L. 
amazonensis infection, attributed to the F1 vaccine (28). The 
enhancement of the IL-10 secretion induced by the F1 vaccine 
[(this investigation) (28, 29)] and YPPEFKTKL indicate that 
this sequence might also be a T regulatory epitope, which 
deserves better characterization. Supporting its universality 
and biological relevance, the YPPEFKTKL sequence was also 
predicted with high scores for the binding of the human Class I 
HLA-A*2402 and HLA-B*0702 molecules, induced the IFN-γ 
secretion by PBMC of asymptomatic, IDR positive human indi-
viduals infected with L. infantum and was found to be highly 
conserved in the NH sequence of all the studied Leishmania 
species (49).
For its multiple capabilities, the YPPEFKTKL epitope might 
be considered as a Pan epitope candidate (51–53). In fact, the 
sequence MDEPTLLYV was described as a PANDR epitope of the 
A15 hexon protein of adenovirus (52) while the synthetic more 
preferably PADRE peptide composition is aKXVAAWTLKAAa 
(54). In order to constitute a PADRE epitope, the peptide should 
contain defined amino acids in R1, R2, R3, R4, and R5 (54). 
Remarkably, and as expected for a PADRE sequence (54), the 
YPPEFKTKL contains Y as the R2 residue, four residues in R3, 
where three to five amino acids are needed, and the sequences 
KT followed by TKL in R4, while the expected combinations for 
R4 are KT, TLK, or WTLK (54). The adenovirus epitope contains 
TLL instead of TLK in the place of R4 (52).
YPPEFKTKL of L. donovani maintains identical sequence in 
the NHs of L. infantum chagasi, L. infantum, L. amazonensis, L. 
major, and L. mexicana (49). TKL is substituted with TNL in L. 
tropica while the second residue of R2, P, is substituted by S in the 
NHs of L. braziliensis and Leishmania panamensis, both of the 
subgenus Vianna (49).
Another common feature of the NH36 epitopes to PADRE 
sequences is found in the KFWCLVIDALKRIG CD4+ predicted 
epitope of F3, which shares with the aKFVAAWTLKAAa of the 
PADRE sequence the first KF residues (54). This epitope induced 
a mild secretion of IFN-γ, TNF-α, and IL-10 and increased fre-
quencies of CD4+ multifunctional T cells.
In spite the intense research on development of anti-Leishma-
nia vaccines in animals models (11, 55) only a few of them are 
the basis of potential synthetic or epitope vaccines. The kmp-11 
(56), the amastigote A2 (57), and the polytope vaccine containing 
LPG-3, LmSTI-1, CPB, and CPC (58) present epitopes for the 
CD8+ T cells. On the other hand, the LACK158–173 peptide 
(59), the amastigote A2 antigen (57), and the MML-triple fusion 
L. major vaccine expressed in adenovirus (37) determined a Th1-
biased CD4 T cell response.
In this investigation, we demonstrated that arrangement 
of the epitopes of the NH of L. donovani NH36 in tandem, 
in a chimera, improved the cross-protection to CL caused 
by L. amazonensis. We found that the chimera optimized the 
vaccine efficacy, probably by increasing the probabilities of 
cross-presentation as a strategy to enhance immunity (44, 45). 
We further advanced in the identification of the most relevant 
epitopes responsible for the immune responses generated by the 
subunit vaccines (17, 28, 29). We found potent epitopes for the 
generation of the CD4+-Th1, cytotoxic and potential T regula-
tory response and recognized among them at least one with 
PADRE capabilities (54). The data gathered in our work will 
help in the development of a polytope vaccine against visceral 
and CL, which will allow to fight the disease with enhanced 
efficacy.
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